These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

493 related items for PubMed ID: 24101072

  • 1. Biosimilars and the European experience: implications for the United States.
    Megerlin F, Lopert R, Taymor K, Trouvin JH.
    Health Aff (Millwood); 2013 Oct; 32(10):1803-10. PubMed ID: 24101072
    [Abstract] [Full Text] [Related]

  • 2. The comparability conundrum: biosimilars in the United States, Europe and Canada.
    Courage N, Parsons A.
    Food Drug Law J; 2011 Oct; 66(2):203-24, i-ii. PubMed ID: 24505840
    [Abstract] [Full Text] [Related]

  • 3. Pharmacovigilance and biosimilars: considerations, needs and challenges.
    Casadevall N, Edwards IR, Felix T, Graze PR, Litten JB, Strober BE, Warnock DG.
    Expert Opin Biol Ther; 2013 Jul; 13(7):1039-47. PubMed ID: 23527621
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Development and regulation of biosimilars: current status and future challenges.
    Tsiftsoglou AS, Ruiz S, Schneider CK.
    BioDrugs; 2013 Jun; 27(3):203-11. PubMed ID: 23553340
    [Abstract] [Full Text] [Related]

  • 7. Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future.
    Grabowski HG, Guha R, Salgado M.
    Health Aff (Millwood); 2014 Jun; 33(6):1048-57. PubMed ID: 24889955
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [The Polish Task Force position statement on safety of biologic treatment with monoclonal antibodies and soluble receptors].
    Jahnz-Rozyk K, Wiesik-Szewczyk E, Grupa Ekspertów.
    Pol Merkur Lekarski; 2014 Jul; 37(217):5-9. PubMed ID: 25154192
    [Abstract] [Full Text] [Related]

  • 14. Biosimilars: are they ready for primetime in the United States?
    Hirsch BR, Lyman GH.
    J Natl Compr Canc Netw; 2011 Aug 01; 9(8):934-42; quiz 943. PubMed ID: 21900222
    [Abstract] [Full Text] [Related]

  • 15. Biosimilar competition in the United States: statutory incentives, payers, and pharmacy benefit managers.
    Falit BP, Singh SC, Brennan TA.
    Health Aff (Millwood); 2015 Feb 01; 34(2):294-301. PubMed ID: 25646110
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Optimizing use and addressing challenges to uptake of biosimilars.
    Leber MB.
    Am J Manag Care; 2018 Nov 01; 24(21 Suppl):S457-S461. PubMed ID: 30452214
    [Abstract] [Full Text] [Related]

  • 19. Biosimilars: biologics that meet patients' needs and healthcare economics.
    McCamish M, Yoon W, McKay J.
    Am J Manag Care; 2016 Sep 01; 22(13 Suppl):S439-S442. PubMed ID: 28719221
    [Abstract] [Full Text] [Related]

  • 20. Biosimilars in oncology: from development to clinical practice.
    Rak Tkaczuk KH, Jacobs IA.
    Semin Oncol; 2014 Apr 01; 41 Suppl 3():S3-S12. PubMed ID: 24767633
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.